Navigation Links
Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
Date:6/21/2013

SAN DIEGO and IRVINE, Calif., June 21, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCQB: SRNE; Sorrento) and IGDRASOL announced today that the companies will present updates of their analyses of proprietary late clinical stage paclitaxel formulations, IG-001 (Cynviloq™) and IG-004 (TOCOSOL® paclitaxel) at the joint meeting of the European Foundation for Clinical Nanomedicine (CLINAM) and the European Technology Platform on Nanomedicine (ETPN) in Basel, Switzerland on June 23 - 26. Sorrento has the right to acquire IGDRASOL pursuant to a previously-announced option agreement, entered into in March 2013.

IGDRASOL'S data mining of the clinical data for both IG-001 and IG-004 has generated exciting insights into the field of nanomedicine, which will be presented at the joint meeting. These findings are highly relevant to the theme of this year's conference, namely "Nanomedicine & Targeted Medicine – the paradigm of precise, highly effective and innocuous medicine for the benefit of patients and mankind".

IG-001 (Cynviloq™) is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries as Genexol-PM®. It has completed Phase 1 or 2 trials in metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and bladder cancer in the U.S. and/or ex-U.S. IGDRASOL is preparing for an "End of Phase 2" meeting scheduled with the U.S. Food & Drug Administration (FDA) in July 2013, regarding the clinical development of Cynviloq™. As an injectable nanoparticle formulation of paclitaxel, Cynviloq™ may be eligible for approval through the FDA's 505(b)(2) bioequivalence regulatory pathway versus albumin-bound paclitaxel (nab-paclitaxel; Abraxane®) in its currently approved MBC and NSCLC ind
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
2. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
3. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
4. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
5. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
6. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
7. Sorrento Therapeutics Awarded Third Phase I STTR Grant
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Echo Therapeutics Announces Closing of Public Offering of Common Stock And Full Exercise of Over-Allotment Option by the Underwriter
10. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
11. Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... SAN FRANCISCO, Calif. , July 6, 2015 /PRNewswire/ ... global pharmaceutical company, and Oculeve, a development-stage medical device ... disease, today announced that they have entered into an ... all-cash transaction.  Under the terms of the agreement, Allergan ... and commercialization milestone payments related to Oculeve,s lead development ...
(Date:7/6/2015)... China Information Technology, Inc. (the "Company" or "CNIT") (Nasdaq ... exchange, and big data solutions in China ... mobile app for Healthcare One Pass, ushering in a ... The Company jointly hosted the launch ceremony with the ... News Net.   The mobile app for Healthcare ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... hospitals scramble to adopt the patient-centered focus that is ... at improving healthcare in the U.S., LodgeNet Healthcare ... engagement solution that encourages patients to become educated, active ... to interact with patients throughout the entire continuum of ...
... EAST BRUNSWICK, N.J. and EDISON, N.J., June 8, ... today announced they had entered into a broad-based ... controlled release products. Under the terms of the ... develop and manufacture products for Amerigen to commercialize ...
Cached Medicine Technology:LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 2LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 3LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 4Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products 2
(Date:7/6/2015)... ... July 06, 2015 , ... Acara Partners, a ... the return of its complimentary educational webinar series for the summer ... creates success for their clients through targeted marketing, sales, digital communications, branding and ...
(Date:7/6/2015)... BC (PRWEB) , ... July 06, 2015 , ... Olive ... received the UBC 2014-2015 Post Graduate Teaching Award on behalf of the department of ... is a very exciting field to be practicing in. The technology is changing so ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... redesigned site allows newly-diagnosed cancer patients, caregivers and medical professionals to chat with ... survived the same cancer. , “Receiving a cancer diagnosis is often the most ...
(Date:7/6/2015)... ... July 06, 2015 , ... MD Now, the leading and ... The newly constructed urgent care center will serve residents and visitors in the Cutler ... being MD Now’s 22nd South Florida location, the new facility will be the fourth ...
(Date:7/6/2015)... ... July 06, 2015 , ... World renowned Los Angeles facial ... their ideal appearance through comprehensive treatment solutions. Individuals that want to make multiple changes ... receive a plan that resolves each of their needs. , "Anytime I see ...
Breaking Medicine News(10 mins):Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:Cancer Hope Network Launches Upgraded Website to Support Cancer Patients, Caregivers 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Los Angeles Plastic Surgeon, Dr. Paul Nassif, is Now Offering Comprehensive Facial Plastic Surgery Procedures 2
... July 24, 2009 -- Half of all Americans will be ... number two killer in the United States. One of the ... to the National Cancer Institute, 192,370 women will be diagnosed ... will die from the disease this year alone. One ...
... , , , SAN ... G. Komen for the Cure, one of over 100 Affiliates nationwide dedicated ... over $1.6 million dollars to support Bay Area breast health education and ... The Komen San Francisco Bay Area Affiliate,s local fundraising ...
... July 24 Yesterday, the U.S. House of Representatives ... prohibits HHS (Health and Human Services) funding for programs which distribute ... such as HIV and hepatitis. The amendment reads as follows: , ... bill (before the short title), insert the following: Sec.___. None ...
... , , FARMINGTON ... provider of aesthetic services in the U.S., announced the launch of ... the training of current and new technicians, clinic managers and corporate ... best in class service and enhance the customer experience. ...
... , COLUMBIA, S.C., July 24 UCI ... Wells, Jr., the former Executive Vice-President of Finance, Chief Financial ... pled guilty on July 23, 2009 in federal court to ... filed with the Securities and Exchange Commission. On the ...
... Taking samples from accident patients may offer a medical ... -- Testing the blood-alcohol level of trauma patients could ... complications from drinking issues, a new study says. ... leaving medical personnel in the dark about potentially serious ...
Cached Medicine News:Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 2Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 3Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 4Health News:Breast cancer research highlights from the American Association of Physicists in Medicine meeting in Anaheim, July 26-30 5Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.2 Million This Year to Community Outreach Programs 2Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.2 Million This Year to Community Outreach Programs 3Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.2 Million This Year to Community Outreach Programs 4Health News:American Laser Centers Announces Launch of 'ALC University' 2Health News:UCI Medical Affiliates, Inc.'s Internal Investigation Leads to Former Executive Officer Pleading Guilty to Criminal Charges 2Health News:Alcohol and Trauma: Blood Test Gets to the Truth 2
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
The Fluoroskan Ascent, a dedicated microplate fluorometer, offers high sensitivity for a wide variety of fluorometric applications....
... is a fixed wavelength fluorometer for ... emission. The spectral characteristics are specifically ... DNA using the standard Hoechst 33258 ... from the presence of protein, RNA, ...
The VICTOR² D fluorometer is suitable for clinical assays based on fluorescence or time-resolved fluorescence from a wide variety of plates....
Medicine Products: